Nanjing Noratech Pharmaceutical Co Ltd
General
Total Cases5
Active Cases4
Patents--
--
--
--
Ratings
Experience
Grade
Trend
DCT
--
--
--
PTAB
--
--
--
CAFC
--
--
--
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 02/07/25 | [SEALED] Proposed Findings of Fact by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # [1] Certificate of Service)(Gattuso, Dominick) (Entered: 02/07/2025) | |
| 02/07/25 | [SEALED] POST TRIAL BRIEF Defendants Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc.'s Answering Brief Regarding Non-Infringement of the 667 by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # [1] Certificate of Service)(Gattuso, Dominick) (Entered: 02/07/2025) | |
| 02/07/25 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/07/2025) | |
| 02/07/25 | POST-TRIAL Answering on Validity of the '667 Patent, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/7/2025 (nms). (Entered: 02/07/2025) | |
| 01/30/25 | ORDER of USCA as to [31] Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Nanjing Noratech Pharmaceutical Co., Ltd. submits a motion to dismiss. Upon consideration thereof. IT IS ORDERED THAT: Any response to the motion to dismiss is due no later than February 6, 2025. (nms) (Entered: 01/30/2025) | |
| 01/29/25 | SO ORDERED Granting Stipulation and Order Regarding Submission of Admitted Exhibits Cited in Post-Trial Briefing (D.I. 165 in 23-cv-401-RGA; D.I. 457 in 22-cv-1395-RGA; D.I. 1754 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 1/29/2025. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 01/29/2025) | |
| 01/28/25 | STIPULATION and Order Regarding Submission of Admitted Exhibits Cited in Post-Trial Briefing by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 01/28/2025) | |
| 01/28/25 | REDACTED VERSION of [155] Proposed Findings of Fact, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 1/28/2025 (nms). (Entered: 01/28/2025) | |
| 01/24/25 | REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [155] . (nms) (Entered: 01/24/2025) | |
| 01/22/25 | SO ORDERED Granting Stipulation and Order Regarding Post-Trial Briefing (D.I. 162 in 23-cv-401-RGA; D.I. 455 in 22-cv-1395-RGA; D.I. 1749 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 1/22/2025. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 01/22/2025) |